Tedisamil in a chronic canine model of atrial flutter

Journal of Cardiovascular Pharmacology

Volumn 34, Issue 2, 1999, Pages 212-218

  Fischbach, Peter S ^a   Johnston, Peter V ^a   Friedrichs, Gregory S ^a   Lucchesi, Benedict R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

ATP dependent potassium channel; Repolarization; Supraventricular tachyarrhythmia

Indexed keywords

NADOLOL; POTASSIUM CHANNEL; TEDISAMIL;

ANIMAL MODEL; ARTICLE; CHRONOTROPISM; CONTROLLED STUDY; DISEASE SIMULATION; DOG; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HEART ATRIUM CONDUCTION; HEART ATRIUM FLUTTER; HEART PROTECTION; HEART REPOLARIZATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; RR INTERVAL; SUPRAVENTRICULAR TACHYCARDIA;

ADENOSINE TRIPHOSPHATE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FLUTTER; BICYCLO COMPOUNDS, HETEROCYCLIC; CHRONIC DISEASE; CYCLOPROPANES; DISEASE MODELS, ANIMAL; DOGS; ELECTROCARDIOGRAPHY; MALE; NADOLOL; POTASSIUM CHANNEL BLOCKERS;

EID: 0032788127     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199908000-00006     Document Type: Article

References (43)

1. + current in rat ventricular myocytes. Am J Physiol 1989;257: H1746-9.
2. + currents in mammalian cardiac and glial cells. J Pharmacol Exp Ther 1990;254:560-9.
3. to blockade? J Cardiovasc Pharmacol 1991;18:445-56.
4. Beatch GN, MacLeod BA, Abraham S, Walker MJ. The in vivo electrophysiological actions of the new potassium channel blockers, tedisamil and UK 68,798. Proc West Pharmacol Soc 1990;33: 5-8.
5. + current in single smooth muscle cells of the guinea-pig portal vein. Pflugers Arch 1992;421:22-5.
6. McLarnon JG, Sawyer D, Michikawa M, Kim SU. Tedisamil blocks a calcium-dependent potassium channel in cultured motoneurons. Neurosci Lett 1992;144:185-8.
7. + channels in membrane patches from smooth muscle cells of the guinea-pig portal vein. Pflugers Arch 1991; 418:308-2.
8. + channels in adult rat ventricular cells. J Mol Cell Cardiol 1992;24:S40.
9. Chi L, Park JL, Friedrichs GS, et al. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol 1996;117:1261-9.
10. Faivre J, Rouanet S, Bril A. Comparative effects of glibenclamide, tedisamil, dofetilide, E-4031 and BRL-32872 on protein kinase A-activated chloride current in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 1988;31:551-7.
11. Bril A, Landais L, Gout B. Actions and interactions of E-4031 and tedisamil on reperfusion-induced arrhythmias and QT interval in rat in vivo. Cardiovasc Drugs Ther 1993;7:233-40.
12. + current blocker. Br J Pharmacol 1991;102:13-8.
13. Wallace AA, Stupienski RF 3rd, Baskin E, et al. Cardiac electrophysiologic and antiarrhythmic actions of tedisamil. J Pharmacol Exp Ther 1995;273:168-75.
14. Dorian P, Newman D. Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements. Cardiovasc Res 1997;33:485-94.
15. Friedrichs GS, Abreu JN, Driscoll EM Jr, Borlak J, Lucchesi BR. Antifibrillatory efficacy of long-term tedisamil administration in a postinfarcted canine model of ischemic ventricular fibrillation. J Cardiovasc Pharmacol 1998;31:56-66.
16. Allessie M, Bonke F, Schopman F. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res 1977; 41:9-18.
17. Frame L, Page R, Hoffman B. Atrial reentry around an anatomic barrier with a partially refractory excitable gap: a canine model of atrial flutter. Circ Res 1986;58:495-511.
18. Task Force of Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.
19. Singh B. The coming of age of the class III antiarrhythmic principle: retrospective and future trends. Am J Cardiol 1996;78(suppl 4A):17-27.
20. Faivre J, Gout B, Bril A. Tedisamil. Cardiovasc Drug Rev 1995; 13:33-50.
21. Baskin E, Lynch J. Differential atrial versus ventricular activities of class III potassium channel blockers. J Pharmacol Exp Ther 1998;285:135-42.
22. Nemeth M, Virag L, Hala O, Varro A, Kovacs G, Thormahlen D, Papp JG. The cellular electrophysiological effects of tedisamil in human atrial and ventricular fibers. Cardiovasc Res 1996;31: 246-8.
23. Nemeth M, Varro A, Virag L, Hala O, Thormahlen D, Papp J. Frequency-dependent cardiac electrophysiologic effects of tedisamil: comparison with quinidine and sotalol. J Cardiovasc Pharmacol 1997;2:273-84.
24. Nichols C, Lederer W. Adenosine triphosphate-sensitive potassium channels in the cardiovascular system. Am J Physiol 1991; 261:H1675-86.
25. Wilde A, Janse M. Electrophysiological effects of ATP sensitive potassium channel modulation: implications for arrhythmogenesis. Cardiovasc Res 1994;28:16-24.
26. Hearse D. Activation of ATP-sensitive potassium channels: a novel pharmacological approach to myocardial protection? Cardiovasc Res 1995;30:1-17.
27. + channels and protects against simulated ischemia in rabbit myocytes. J Mol Cell Cardiol 1997;29:1123-30.
28. Spinelli W, Follmer C, Parsons R, Colatsky T. Effects of cromakalim, pinacidil and nicorandil on cardiac refractoriness and arterial pressure in open chest dogs. Eur J Pharmacol 1990;179:243-52.
29. Friedrichs G, Abreu J, Cousins G, Chi L, Borlak J, Lucchesi BR. Tedisamil attenuates ventricular fibrillation in a conscious canine model of sudden cardiac death. J Cardiovasc Pharmacol 1996;1: 313-24.
30. Oexle B, Weirich JHA. Electrophysiological profile of KC8857, a new bradycardic agent. J Mol Cell Cardiol 1987;19:S65.
31. Roden D. Early afterdepolarizations and torsades de pointes: implications for the control of cardiac arrhythmias by controlling repolarization. Eur Heart J 1993;14(suppl H):56-61.
32. Bianconi L, Boccadamo R, Pappalardo A, Gentilli C, Pistolese M. Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 1989;63: 693-6.
33. Falk R. Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation. Ann Intern Med 1989;111: 107-11.
34. Feld G, Chen P, Nicod P, Fleck R, Mezer D. Atrial proarrhythmic effects of class IC antiarrhythmic drugs. Am J Cardiol 1990;66: 378-83.
35. Madrid A, Moro C, Marin-Huerta E, Mestre J, Novo L. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-31.
36. Singh B. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Am J Cardiol 1996;78(suppl 4A):41-53.
37. Kou W, Nelson S, Lynch J, Montgomery D, DiCarlo L, Lucchesi B. Effect of flecainide acetate on prevention of electrical induction of ventricular tachycardia and occurrence of ischemic ventricular fibrillation during the early postmyocardial infarction period: evaluation in a conscious canine model of sudden death. J Am Coll Cardiol 1987;9:359-65.
38. Lynch J, DiCarlo L, Montgomery D, Lucchesi B. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. Pharmacology 1987;35-181-93.
39. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;21:406-12.
40. Thormann J, Mitrovic V, Strasser R, et al. Is the bradycardic effect of tedisamil at the expense of the loss of the inotropic effect? A pressure-volume analysis with the conductance (volume) catheter technique in patients with coronary artery disease. Z Kardiol 1993; 82:211-21.
41. Thormann J, Mitrovic V, Riedel H, et al. Tedisamil (KC 8857) is a new specific bradycardic drug: does it also influence myocardial contractility? Analysis by the conductance (volume) technique in coronary artery disease. Am Heart J 1993;125:1233-46.
42. Bargheer K, Bode F, Klein HU, Trappe HJ, Franz MR, Lichtlen PR. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J 1994;15:1409-14.
43. Demolis JL, Martel C, Funck-Brentano C, Sachse A, Weimann HJ, Jaillon P. Effects of tedisamil, atenolol and their combination on heart and rate-dependent QT interval in healthy volunteers. Br J Clin Pharmacol 1997;44:403-9.